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Abstract: (1) Background: The high heterogeneity of inflammatory bowel disease (IBD) makes the
study of this condition challenging. In subjects affected by Crohn’s disease (CD), extra-intestinal
manifestations (EIMs) have a remarkable potential impact on health status. Increasing numbers of
patient characteristics and the small size of analyzed samples make EIMs prediction very difficult.
Under such constraints, Bayesian machine learning techniques (BMLTs) have been proposed as a
robust alternative to classical models for outcome prediction. This study aims to determine whether
BMLT could improve EIM prediction and statistical support for the decision-making process of
clinicians. (2) Methods: Three of the most popular BMLTs were employed in this study: Na
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1. Introduction 
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intestinal manifestations (EIMs) significantly impact health status. Several European studies report 
EIMs are present in 20–40% of Crohn’s disease (CD) patients, are more common in females than males 
and are associated with a duration of disease >10 years (48.9% vs. 29.9% in patients with diseases <10 
years) [1–3]. Joint manifestations (peripheral or axial arthropathies) are the most common EIMs in 
IBD and occur in 20–30% of patients, with symptoms ranging from noninflammatory arthralgia to 
acute arthritis with painful swollen joints, usually associated with active IBD [4]. Articular 
manifestations may be more frequent in CD patients with stenosing/penetrating disease [4]. 
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1. Introduction
Inflammatory bowel disease (IBD) can have various clinical presentations, making the classification
of patients very chall nging. In subjects affected by Crohn’s disease (CD), extra-intestinal ma ifestations
(EIMs) signific ntly impact health status. Several European studies report EIMs re present in 20–40%
of Crohn’s disease (CD) patie ts, re more ommon in females than mal s and are ass ciated
with a duration of disease >10 years (48.9% vs. 29.9% in pati nts with diseases <10 years) [1–3].
Joint manifestations (peripheral or xial arthropathies) are the most common EIMs in IBD and
occur in 20–30% of patient , with symptoms ranging from noninflam atory arthralgia to acute
rthritis with painful swollen joints, usually associated with active IBD [4]. Articular manifestations
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may be more frequent in CD patients with stenosing/penetrating disease [4]. Erythema nodosum,
pyoderma gangrenosum, and aphthous stomatitis are the most common cutaneous manifestations in
IBD. Prevalence rates are 5–15% in CD patients with female predominance, and they parallel disease
activity in up to 92% of episodes and may recur in approximately 20–30% of patients [5]. The most
common ocular manifestations include uveitis and episcleritis. Their prevalence is between 3% and 6%
in CD, and they are associated with disease activity in up to 78% of episodes, with recurrent episodes
in approximately 30% of patients [5]. Ocular manifestations may frequently occur together with other
(joint or cutaneous) EIMs [6]. Primary sclerosing cholangitis (PSC) may be present in 0.7–2% patients
with CD; however, if small-duct PSC is included, the overall prevalence ranges from 2.4 to 11% [4,7].
Many strategies have been proposed to appraise the role played by genetic factors in the risk
of EIMs occurrence [8]. Knowledge of the risk of EIMs associated with a patient’s characteristics is
important for better planning and more tailored treatment strategies [9]. Nevertheless, the relationship
between the genetic characteristics of the patient and the occurrence of EIMs remains unclear [10].
Predicting the occurrence of EIMs on the basis of a patient’s characteristics is a challenging task
for two main reasons: there is an increasing amount of information on subjects’ characteristics and a
limited number of patients for whom data are available [11–13]. The high complexity of EIM prediction
requires more powerful and complex statistical methods that provide valuable information from a
clinical point of view. Indeed, traditional statistical methods, such as simple/multivariate logistic
regression, may not represent the best solutions to characterize such a complex risk structure, which
may often be characterized by nonlinear relationships between outcome and predictors and interactions
among covariates.
Traditional Machine Learning Techniques (MLTs) have been promoted as a promising approach for
modeling the role of genetic factors in EIM prediction [14]. The integration of the Bayesian frameworks
in the MLTs field has been recently proposed and the use of Bayesian machine learning techniques
(BMLTs) is rapidly becoming popular in the medical setting. The ability of these methods to embrace the
modeling flexibility of MLTs [15–17] with the advantages of Bayesian inference makes them potentially
robust in situations in which standard methods may fail, such as handling missing data, robustness to
overfitting in presence of small sample size and embedding of external information [18,19].
Some of the most used BMLTs in the medical field are Na
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1. Introduction 
Inflammatory bowel disease (IBD) can have various clinical presentations, making the 
classification of patients very challenging. In subjects affected by Crohn's disease (CD), extra-
intestinal manifestations (EIMs) significantly impact health status. Several European studies report 
EIMs are present in 20–40% of Crohn’s disease (CD) patients, are more common in females than males 
and are associated with a duration of disease >10 years (48.9% vs. 29.9% in patients with diseases <10 
years) [1–3]. Joint manifestations (peripheral or axial arthropathies) are the most common EIMs in 
IBD and occur in 20–30% of patients, with symptoms ranging from noninflammatory arthralgia to 
acute arthritis with painful swollen joints, usually associated with active IBD [4]. Articular 
manifestations may be more frequent in CD patients with stenosing/penetrating disease [4]. 
ve Bayes (NB) and Bayesian Network
[20–23]. Additionally, in the la t few y ars, Bayesian Additive Regression Trees (BART) have
been emerging as a frequent choice [24,25].
The go l of this study is to understand whether the prediction of EIMs using patients’ clinical and
genetic characteristics is enhanced by using novel and existing BMLT approaches. Moreover, we aim
to c the predictive performances of these m thods to provide suggestions and support in terms
of implementation of mod ling strategies.
2. Material and Methods
The dataset employed in this study is the same set used in Giachino et al. [14]. It refers to
an observational study on the role of genetic factors for IBD. Information on subjects with CD and
ulcerative colitis (UC) was retrieved in cooperation with three gastroenterology units in Torino, Italy.
Overall, 152 subjects were enrolled in the study. Clinical and familial information on patients was
acquired and labeled following the Vienna classification employed at the time of the study. EIMs were
defined as manifestations of rheumatological, dermatological, ocular, liver, biliary, and amyloidosis
ymptoms. Patient ch racteristics that could pote tially affect EIM occurrence were retrieved and
divided into two main groups: (i) characterist cs of the dis ase and factors that are known to be
assoc ated with the clinical endpoint— ge at onset (age), location (location), behavior (behavior),
presentation of the dis ase (onset), gender (gender), smoker status (smoker), family history (history);
and (i ) genetic polymorphism of the follow ng genes: NOD2, CD14, TNF, IL12B and IL1RN.
According to the Vienna clas ification, patients are defined as A1 if the diagnosis is made before
40 years of age and A2 if it was ade after 40 years of age. Regarding location, L1 corresponds to
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disease located in the terminal ileum and possibly involving the caecum, L2 corresponds to colonic
disease, L3 to ileocolonic disease, and L4 to CD involving the upper gastrointestinal tract (irrespective
of the other locations of the disease). Regarding behavior, B1 corresponds to a non-structured and
nonpenetrating disease, B2 to a structured disease, and B3 to a penetrating disease.
Presentation of the disease (onset) refers to medical when a medical diagnosis related to signs
and symptoms that provided a suggestion of Crohn’s disease to a medical doctor was made without
previous bowel surgery. Surgical refers to cases when the first event of CD was surgery; i.e., a patient
was admitted to a hospital for a surgical indication, and a diagnosis of Crohn’s disease was made during
the surgical operation or was based on histological analysis of the removed bowel. Family history
refers to having a relative with CD (the strongest risk factor for CD, i.e., first-degree relatives of patients
with CD have a 12- to 15-fold greater risk of developing CD than do people of comparable age in the
general population).
2.1. BMLTs
NB, BN, and BART are marked by high flexibility and good prediction ability, which make them
very popular among BMLTs and widely applied in the medical field [26].
The NB classifier can be represented as a simple Directed Acyclic Graph (DAG), and is very
easy to build. In graphical notation, each variable is represented by a node, and the relationships
between variables are described by arcs with edges from node to node. The simplicity of NB lies
in its naïve assumptions, i.e., the outcome variable is considered the parent node of all other nodes,
which are also called child nodes, and there is no connection between child nodes [27]. The fixed
structure of this graph makes its implementation very simple. Once the structure of the graph is built,
classification is carried out using Bayes’ theorem by computing the posterior predictive distribution of
the probability of observing the outcome of interest given the posterior distributions of the parameters.
In the literature, the NB classifier has been shown to perform well [28], especially with small sample
size datasets [29].
BNs are DAGs [30] that model the joint probability distribution of a set of variables. The graphical
structure of a BN can be implemented by imposing the relationships between nodes with expert
opinions on the phenomenon under study or by defining the connections between the variables with
learning algorithms. Bayes’ theorem is then used to compute the conditional probabilities of the
parameters of the models given the values of the variables, which quantify the relationships among
nodes connected. Like NBs, BNs provide information on the probability that an event of interest will
occur, given the values of the nodes to which the outcome node is connected. From a clinical point
of view, this can be very helpful for a researcher to profile patients given the predicted event risks
associated with several characteristics.
BART was introduced by Chipman et al. (2010) [31]. It belongs to the popular family of
“ensemble-of-trees” methods, such as Bagging, Random Forest, and Boosting. BART is essentially a
sum-of-trees model: it describes the relationship between an outcome of interest and a set of covariates
as a sum of many regression or classification trees plus a random component. The contribution of each
tree to the total sum is weakened by imposing regularizing prior distributions on the parameters that
control the sum-of-trees. Regularizing priors are then able to prevent the contribution of a single tree
from dominating the total sum, avoiding the problem of overfitting. BART is then able to provide
information on the probability of occurrence of an event of interest given subject characteristics by
flexibly relating the clinical endpoint to the potential explanatory variables.
In summary, NB and BN are both graphical models. The former imposes a fixed structure on
the network and, despite its strong unrealistic assumptions, it has performed very well in several
situations [32]. The latter learns the structure of the network using several algorithms or by relying on
expert opinions, which makes its classification ability highly dependent on the learning procedure.
Several studies compared NB and BN, showing that both techniques have similar performance [33–35].
Moreover, many studies compared the performance of NB and BN with other classical MLTs, showing
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that they have similar predictive performances with respect to the other classical methods [36–40].
BART belongs to the family of ensemble-of-trees models, and its regularizing prior distributions and
ability to put together weak classifiers avoid overfitting. It is a good alternative to other more popular
MLTs, such as lasso regression, random forest, and neural networks [31].
2.2. Statistical Analysis
Patients were classified according to the presence or absence of EIMs if the predicted probability
of the event was higher than 0.5.
Missing data were inferred with the same strategies used in the study of Giachino et al. [14]: the
median of available sample values for continuous variables and an additional level indicating the
presence of missingness for categorical variables.
BMLTs were compared with the statistical approaches employed in the study of Giachino et al. [14],
i.e., logistic regression (LR), generalized additive model (GAM), projection pursuit regression (PPR),
linear discriminant analysis (LDA), quadratic discriminant analysis (QDA), and artificial neural
networks (ANN). Statistical analysis was implemented following the same model validation approach
adopted in the study mentioned above to perform a fair comparison. Parameters of the models were
chosen using repeated k-fold cross-validation, setting the number of folds equal to 10 and repeating
the process 10 times. Regarding BART models, the Gibbs sampler was used to draw from the posterior
distribution using 2000 draws and discarding the first 500 as “burn-in” draws. Convergence of the
posterior distribution was assessed by inspecting the acceptance percentage of MCMC proposals
across the trees, the average number of leaves, and tree depth at each MCMC iteration after the
“burn-in” draws. All of the patients in the sample were considered in the training set. Since no
external data for testing the models were available, model validation was carried out using 1000
bootstrapped samples of the original dataset [41], a procedure that has been shown to give unbiased
estimates of the error rate [42]. The ability to correctly classify the presence or absence of EIMs
was evaluated by comparing several indicators: Somers’ Dxy (Somers’ D), positive and negative
predicted values of model predictions (PPV and NPV, respectively), overall misclassification error
(MCR, which corresponds to the percentage of observations wrongly classified) and the area under the
ROC curve (AUC). Moreover, the sensitivity and specificity of BMLTs were also assessed to provide
more information on their predictive ability. We did not use the discrimination index—defined as the
likelihood ratio divided by the sample size [42]—to compare the techniques as in Giachino et al. [14].
Rather, following Gelman and Rubin [43], we preferred to explore their posterior distributions by
means of their ability to correctly classify patients according to the indicators mentioned above.
For each model, two analyses were performed: one including only the first group of potential
explanatory variables as covariates, and one also including genetic variables. Such a strategy was
conducted to evaluate the impact that genetic factors have on the overall ability of the models to predict
the presence or absence of EIMs.
Regarding the analysis with BN, two elucidations needed to be done. First, several algorithms
can be used to learn the structure of the network. The choice of the algorithm is nontrivial, and
currently, no rigorous method covers this issue. Since the definition of a procedure for choosing the
best algorithm is beyond the scope of this study, the network that achieved the lowest MCR was
selected. Second, to implement a more robust model, the structure of the network was chosen with a
model averaging approach for each algorithm [44]. The structural learning process was repeated on
1000 bootstrap replicates of the original sample, and the structure of the network was created according
to the approach in Scutari and Nagarajan (2013) [45].
All analyses were performed using version 3.4.3 of R software [46] on a HP ProDesk 490
G3 MT Business PC with a Inter(R) Core(TM) i7-6700 CPU @ 3.40GHz processor. NB and BN
were implemented using the “bnlearn” package [47], while BART was implemented using the
“bartMachine” package [48]. Default prior distributions of the “bnlearn” package were used for NBs
and BNs. The data that support the findings of this study are available from the corresponding author
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upon request. The R code to simulate the data and reproduce the analysis is available on Github
(https://github.com/UBESP-DCTV/ibd-bmlt).
3. Results
The distributions of the patient’s characteristics by absence/presence of EIMs are reported in
Table 1. Overall, 75 subjects (nearly 49%) had EIMs, whereas 77 patients (nearly 51%) did not have
EIMs. Onset, behavior, location, age, family history, and polymorphism of NOD2 and CD14 showed
similar distributions across patients with and without EIMs, whereas the distributions of the other
variables were more unbalanced.
Table 1. Distributions of patient characteristics across the absence or presence of EIMs. EIMs = No
indicates absence of EIMs, EIMs = Yes indicates presence of EIMs. n* refers to the number of records
without missing entries.
Variable (n*) EIM = No,
n (%)
N = 77
EIM = Yes,
n (%)
N = 75
Combined,
n (%)
N = 152
Onset (147) Medical 70 (90.9) 63 (84.0) 133 (87.5)
Surgical 7 (9.1) 7 (9.3) 14 (9.2)
Behavior (108) B1 25 (32.5) 25 (33.3) 50 (32.9)
B2 15 (19.5) 20 (26.7) 35 (23.0)
B3 9 (11.7) 14 (18.7) 23 (15.1)
Location (109) L1 14 (18.2) 14 (18.7) 28 (18.4)
L2 11 (14.3) 14 (18.7) 25 (16.4)
L3 21 (27.3) 27 (36.0) 48 (31.6)
L4 4 (5.2) 4 (5.3) 8 (5.3)
Age (146) A1 53 (68.8) 51 (68.0) 104 (68.4)
A2 21 (27.3) 21 (28.0) 42 (27.6)
Gender (152) M 46 (59.7) 34 (45.3) 80 (52.6)
F 31 (40.3) 41 (54.7) 72 (47.4)
Smoker (146) No 42 (54.5) 36 (48.0) 78 (51.3)
Yes 19 (24.7) 26 (34.7) 45 (29.6)
Ex 11 (14.3) 12 (16.0) 23 (15.1)
Family History (139) No 58 (75.3) 57 (76.0) 115 (75.7)
Yes 11 (14.3) 13 (17.3) 24 (15.8)
NOD2:R702W (152) RR 63 (81.8) 64 (85.3) 127 (83.6)
RW 11 (14.3) 9 (12.0) 20 (13.2)
WW 3 (3.9) 2 (2.7) 5 (3.3)
G908R (152) GG 73 (94.8) 67 (89.3) 140(92.1)
GR 4 (5.2) 8 (10.7) 12 (7.9)
L1007fs (152) LL 71 (92.2) 65 (86.7) 136 (89.5)
L/insC 5 (6.5) 8 (10.7) 13 (8.6)
insC/insC 1 (1.3) 2 (2.7) 3 (2.0)
CD14 (152) CC 20 (26.0) 20 (26.7) 40 (26.3)
TC 39 (50.6) 36 (48.0) 75 (49.3)
TT 18 (23.4) 19 (25.3) 37 (24.3)
TNF-308 (72) GG 35 (45.5) 18 (24.0) 53 (34.9)
GA 9 (11.7) 4 (5.3) 13 (8.6)
AA 5 (6.5) 1 (1.3) 6 (3.9)
TNF -238 (72) GG 49 (63.6) 23 (30.7) 72 (47.4)
IL12B (72) AA 17 (22.1) 11 (14.7) 28 (18.4)
AC 24 (31.2) 10 (13.3) 34 (22.4)
CC 8 (10.4) 2 (2.7) 10 (6.6)
IL1RN (72) ILRN*1 29 (37.7) 12 (16.0) 41 (27.0)
ILRN*1/ILRN* 15 (19.5) 7 (9.3) 22 (14.5)
ILRN*2 3 (3.9) 3 (4.0) 6 (3.9)
ILRN*1/ILRN* 1(1.3) 1 (1.3) 2 (1.3)
ILRN*2/ILRN* 1 (1.3) 0 1 (0.7)
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MCRs of the BNs learned with different algorithms are reported in Table 2. All the available
algorithms in the “bnlearn” package were used to learn the structure of the network. Among the
models without genetic variables, the network learned with the SI-HITON-PC algorithm showed the
lowest MCR, whereas the poorest performance was observed for the networks learned with the IAMB,
Fast-IAMB, and TS algorithms. Among the models with the genetic variables, the best performances
were observed for the networks learned with the TS and the HC algorithms, whereas the network
learned with the IAMB algorithm showed the highest MCR.
Table 2. MCR of the networks learned with different algorithms. The selected algorithms were the
ones implemented in the “bnlearn” R package. Performances for networks with and without genetic
variables are reported.
Learning algorithm MCR
Model without genetic variables
Grow-Shrink (GS) 0.57
Incremental Association Markov-Blanket (IAMB) 0.61
Fast Incremental Association Markov-Blanket
(Fast-IAMB) 0.61
Interleaved Incremental Association Markov-Blanket
(Inter-IAMB) 0.59
Hill-Climbing (HC) 0.57
Tabu-Search (TS) 0.61
Max-Min Hill-Climbing (MMHC) 0.53
Restricted Maximization (RSMAX2) 0.60
Max-Min Parents and Children (MMPC) 0.55
Hiton Parents and Children (SI-HITON-PC) 0.51
Chow-Liu (CL) 0.56
ARACNE 0.58
Model with genetic variables
Grow-Shrink (GS) 0.57
Incremental Association Markov-Blanket (IAMB) 0.62
Fast Incremental Association Markov-Blanket
(Fast-IAMB) 0.61
Interleaved Incremental Association Markov-Blanket
(Inter-IAMB) 0.59
Hill-Climbing (HC) 0.34
Tabu-Search (TS) 0.34
Max-Min Hill-Climbing (MMHC) 0.53
Restricted Maximization (RSMAX2) 0.60
Max-Min Parents and Children (MMPC) 0.56
Hiton Parents and Children (SI-HITON-PC) 0.51
Chow-Liu (CL) 0.57
ARACNE 0.58
Performance indexes are reported in Table 3. MCRs of LR, GAM, PPR, LDA, QDA, and ANN are
taken from the study of Giachino et al. [14].
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Table 3. Indicators of classification ability of the model both with and without genetic variables. Values
for LR, GAM, PPR, LDA, QDA, and ANN are the same reported in Giachino et al. [14].
MCR Sensitivity Specificity PPV NPV AUC Somer’s D
Model without genetic variables
LR 0.46 _ _ 0.77 0.52 0.72 0.45
GAM 0.44 _ _ 0.81 0.53 0.72 0.45
PPR 0.36 _ _ 0.98 0.58 0.82 0.64
LDA 0.49 _ _ 0.98 0.52 0.70 0.40
QDA 0.49 _ _ 0.72 0.52 0.67 0.34
ANN 0.38 _ _ 0.94 0.57 0.79 0.58
NB 0.34 0.45 0.81 0.68 0.65 0.71 0.42
BN 0.50 1.00 0.00 0.51 0.49 0.50 0.00
BART 0.32 0.64 0.68 0.67 0.69 0.76 0.51
Model with genetic variables
LR 0.39 _ _ 0.89 0.56 0.77 0.53
GAM 0.37 _ _ 0.90 0.57 0.77 0.54
PPR 0.30 _ _ 0.99 0.62 0.94 0.87
LDA 0.38 _ _ 0.99 0.57 0.77 0.53
QDA 0.22 _ _ 0.74 0.52 0.88 0.75
ANN 0.33 _ _ 0.92 0.60 0.87 0.73
NB 0.33 0.65 0.69 0.69 0.66 0.75 0.51
BN 0.34 0.64 0.69 0.68 0.65 0.67 0.33
BART 0.32 0.66 0.69 0.67 0.69 0.78 0.56
Regarding models without genetic variables, NB performed similarly to the six techniques
employed in the previous study, showing a slightly lower MCR value (0.34), higher NPV value
(0.65), and lower PPV value (0.68). A sensitivity and a specificity of 0.45 and 0.81, respectively, were
observed. The BN chosen for analysis was the one learned with the Hiton Parents and Children
(SI-HITON-PC) algorithm, which was the network with the lowest MCR. The performance was
very poor, as suggested by the performance indicator values (MCR = 0.50, PPV = 0.51, NPV = 0.49,
AUC = 0.50), and it had practically no ability to correctly discriminate between the presence and
absence of EIMs (specificity = 0.00 and Somer’s D = 0.00). BART showed slightly better values for
performance indicators than NB and BN (MCR = 0.32, sensitivity = 0.64, specificity = 0.68, PPV = 0.67,
NPV = 0.69, AUC = 0.76, Somer’s D = 0.51), but no consistent improvement was achieved concerning
the statistical methods previously employed.
When considering genetic variables, NB slightly improved the performance, with higher indicator
values compared to those achieved without genetic variables. With respect to the techniques in
Giachino et al. [14], it showed a similar MCR value (MCR = 0.33), lower PPV, AUC and Somer’s D
values (PPV = 0.69, AUC = 0.75, Somer’s D = 0.51) and a higher NPV value (NPV = 0.66). Sensitivity
and specificity were equal to 0.65 and 0.69, respectively. Among the BNs, the network learned with
Tabu-Search (TS) and Hill-Climbing (HC) algorithms showed the same structure achieving the lowest
MCRs. For comparison purposes, the network learned by TS was selected. Predictive performance was
not satisfactory: despite higher values with respect to the BN without genetic variables, BN performance
metrics were still lower than those reported in Giachino et al. [14] (PPV = 0.68, NPV = 0.65, AUC = 0.67,
Somer’s D = 0.33); however, MCR showed a similar value (0.34). A sensitivity and a specificity of
0.64 and 0.69, respectively, were observed. Like NB, BART improved its performances when also
considering genetic factors. With respect to the previous results in Giachino et al. [14], it showed similar
MCR, AUC and Somer’s D values, a lower PPV value and a higher NPV value (MCR = 0.32, sensitivity
= 0.66, specificity = 0.69, PPV = 0.67, NPV = 0.69, AUC = 0.78, Somer’s D = 0.56). Convergence of
the posterior distribution was reached for both BART models: the acceptance percentage of MCMC
proposals across the trees, the average number of leaves and tree depth at each MCMC iteration after
the “burn-in” period showed stationary processes.
The analyses with NB and BN took less than 2 min. The analysis carried out with BART was
computationally expensive and took approximately 7 h.
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4. Discussion
In the current study, BMLTs did not show any major improvements in classification accuracy
compared to the methods reported in Giachino et al. [14]. In many scenarios, especially when genetic
information was also considered, they performed worse. Models with genetic variables showed better
performance metrics than models without genetic information. Nevertheless, the improvement did
not seem as strong as that shown in Giachino et al. [14], with the exception of BN.
Very low performances of BN without genetic factors were observed because the network was
not able to associate the node of the clinical endpoint (i.e., the appearance of EIMs) to any other node.
Indeed, since the outcome node was not present in the structure of the network, the BN was not able to
discriminate between the presence and absence of EIMs, and it classified all of the individuals with
a presence of EIMs (EIMs+). By adding genetic factors to the BN, the outcome was included in the
network (Figure 1), which allowed it to achieve a higher predictive performance.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 8 of 13 
 
percentage of MCMC proposals across the trees, the average number of leaves and tree depth at each 
MCMC iteration after the “burn-in” period showed stationary processes.  
The analyses with NB and BN took less than 2 min. The analysis carried out with BART was 
computationally expensive and took approximately 7 h. 
4. Discussion 
In the current study, BMLTs did not show any major improvements in classification accuracy 
compared to the methods reported n Giachino et al. [14]. In any scenarios, especially when genetic 
information was also conside ed, they performed worse. Model  with genetic variables showed 
better perform nce metrics than models without genetic inf rmation. N v rtheless, the improvement 
did not seem as strong s that sho n in Giachino et al. [14], with the xception of BN. 
Very low performances of BN w thout g netic factors wer  observed because the network was 
not able to associate the ode of the cl nical endpo nt (i.e., the appearanc  of EIMs) to any othe  node. 
Indeed, since the outcome node was not present in the structure of the n twork, the BN was not abl  
to iscriminate between the presence and absence of EIMs, and it classified all of the individuals wi h 
a presence of EIMs (EIMs+). By addi g genetic factors to the BN, the outcome was inclu ed in the 
network (Figure 1), which allowed it to achieve a higher predictive p rformance.  
 
Figure 1. Structure of the Bayesian network estimated considering demographical variables, known 
risk factors and genetic factors. The red node is the clinical endpoint, which indicates the presence or 
absence of EIMs. The chosen network was learned with the Tabu Search algorithm, which is one of 
the available algorithms in the “bnlearn” R package. 
Even though the BN structure with genetic factors was much more articulated and complex than 
the BN structure without genetic factors, only a few connections between the variables were found 
in both networks. The structure of the networks learned with all of the other algorithms was further 
investigated for both scenarios with and without genetic factors. Regarding BN without genetic 
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Figure 1. Structure of the Bayesian network estimated considering demographical variables, known
risk factors and genetic factors. The red node is the clinical endpoint, which indicates the presence or
absence of EIMs. The chosen network was learned with the Tabu Search al orit m, which is one of the
avail ble algorithms in the “bnlearn” R package.
Even though the BN structure with genetic factors was much more articulated and complex than
the BN structure without genetic factors, only a few connections between the variables were found
in both netw rks. The structure of the networks learned with all of the other algorithms was further
investigated for both scenarios with and without genetic factors. Regarding BN without genetic factors,
most of the networks showed an identical structure (the same structure of the network used in the
analysis). Even with a more complicated structure, the ode of the clinical endpoint was n t included
in the structure. Adding genetic factors, only networks learned with TS and HC algorithms showe
some degree of complexity in their structures, which also include the outcome node.
The predictive performances of BMLTs were investigated by looking at the individual predicted
probabilities of the presence of EIMs assigned by each model averaged across every bootstrap sample
(Table 4). Two interesting findings were observed. First, all BMLTs predicted individual probabilities
of the presence of EIMs less than 0.5 from the first patient to the 72nd patient. From the 73rd patient
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to the last patient, all BMLTs assigned individual probabilities over 0.5. This was probably because
after the 73rd patient, all of the information for the genes IL12B, TNFA-308, TNFA-238, and IL1RN was
systematically missing, indicating that this portion of missing values could be considered as missing
not at random (MNAR). This missing pattern likely affected the performance of the models: patients
with missing information for the genes IL12B, TNFA-308, TNFA-238, and IL1RN were classified as
having EIMs, since a probability higher than 0.5 was assigned to them, whereas the opposite predictive
pattern was observed for patients without missing information for the genes. Indeed, looking at
Figure 2, IL12B and TNFA-238, two of the four variables that were MNAR, played a crucial role in
the BN structure and therefore in predicting the presence of EIMs. Figure 2 displays BART variable
importance, indicating the proportion of times a variable is considered in the definition of the splitting
rule on each of the trees constructed by the model. The “Missing” category of gene TNFA-238 played
an important role in the definition of the model.
From a clinical perspective, the relationship between TNFA-308 and gender depicted in Figure 2
raises some issues since it is somewhat counterintuitive. The unexpected link between TNF-α single
nucleotide polymorphism (-308G>A, rs1800629) and gender may be somehow explained by the
increased prevalence of association between ADA (22G>A) and TNF-α (-308G>A) polymorphisms in
Italian males investigated by Napolioni and Predazzi [49].
Table 4. Average individual predicted probabilities for the presence of EIMs assigned by each model
across each bootstrap replicate of the original sample. From the patient with ID = 73 to the last patient,
entries for the genetic factors IL12B, TNFA-308, TNFA-238, and IL1RN were systematically missing.
ID EIMs IL12B TNFA-308 TNFA-238 IL1RN NB BN BART
63 NO AC GG GG ILRN*1 0.06 0.36 0.26
64 NO AA GG GG ILRN1/ILRN3 0.13 0.36 0.29
65 NO AC GG GG ILRN*1 0.15 0.36 0.48
66 NO AA GG GG ILRN*1 0.22 0.36 0.48
67 NO AC GG GG ILRN*1 0.02 0.36 0.35
68 NO AC GG GG ILRN*1 0.03 0.36 0.31
69 NO AA GA GG ILRN1/ILRN2 0.09 0.36 0.32
70 NO AA AA GG ILRN*1 0.04 0.36 0.37
71 YES AA GA GG ILRN*1 0.02 0.36 0.28
72 YES AA GG GG ILRN*2 0.28 0.36 0.36
73 YES Missing Missing Missing Missing 0.91 0.65 0.65
74 NO Missing Missing Missing Missing 0.69 0.65 0.61
75 YES Missing Missing Missing Missing 0.98 0.65 0.70
76 YES Missing Missing Missing Missing 0.95 0.65 0.65
77 YES Missing Missing Missing Missing 0.97 0.65 0.64
78 YES Missing Missing Missing Missing 0.95 0.65 0.68
79 YES Missing Missing Missing Missing 0.98 0.65 0.70
80 YES Missing Missing Missing Missing 0.88 0.65 0.68
81 YES Missing Missing Missing Missing 0.93 0.65 0.68
82 YES Missing Missing Missing Missing 0.98 0.65 0.75
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Figure 2. Important variables of BART with genetic factors. On the x-axis, the explanatory variables
and their associated levels are shown. The first part of the label refers to the name of the explanatory
variable, whereas the second part refers to the label of the classification. Variable labels are reported in
Table 1. On the y-axis, the percentage of times for each variable was used to determine a splitting rule.
4.1. Study Limitations
Systematic missing entries for the IL12B, TNFA-308, TNFA-238, and IL1RN genes in some patients
highly affected the performance of the models.
Moreover, the predictive posterior risk of EIMs was dichotomized to identify the presence of EIMs
(presence of EIMs if the risk was higher than 0.5) as in the study from Giachino et al. [14] to make the
comparison as fair as possible. As noted in many studies [50–53], the dichotomization of continuous
variables results in a loss of information. The potential gains obtained by exploiting the full posterior
predictive probability of EIMs will be explored in future research studies.
Finally, the procedure adopted to choose which BN to use during the analysis was quite simplistic,
although it represents a default approach in terms of BN tuning. Robust methods that can define the
best algorithm in terms of structure learning should be investigated.
4.2. Final R marks
This study shows that emerging BMLTs do not provide a major improvement in correctly
classifying the presence of EIMs compared to the classical statistical tools. When genetic variables are
considered in the models, they show even lower performances with respect to the classical methods
employed in the study from Giachino et al. [14]. The limited sample size of the datasets and absence
of an external source of data most likely limited the validation process and the predictive ability of
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the models. Nevertheless, BMLTs were expected to improve risk prediction in situations where the
available amount of data and information is not optimal to build predictive models, as in our study.
Our findings did not support the expectations, and some issues may arise around preference for BMLTs
over other classical methods.
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